T. E. King, W. Z. Bradford, S. Castro-bernardini, E. A. Fagan, I. Glaspole et al., ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, vol.370, issue.22, pp.2083-92, 2014.

H. Taniguchi, M. Ebina, Y. Kondoh, T. Ogura, A. Azuma et al., Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis, Eur Respir J, 2010.

B. Ley, J. Swigris, B. M. Day, J. L. Stauffer, K. Raimundo et al., Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis, Am J Respir Crit Care Med, vol.196, issue.6, pp.756-61, 2017.

V. Cottin, D. Koschel, A. Günther, C. Albera, A. Azuma et al., Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study, ERJ Open Res, vol.4, issue.4, pp.84-2018, 2018.

U. Costabel, C. Albera, W. Z. Bradford, P. Hormel, T. E. King et al., Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis, vol.31, pp.198-205, 2014.

U. Costabel, C. Albera, L. H. Lancaster, C. Y. Lin, P. Hormel et al., An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP), Respiration, vol.94, issue.5, pp.408-423, 2017.

D. J. Lederer, W. Z. Bradford, E. A. Fagan, I. Glaspole, M. K. Glassberg et al.,

, Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis, Chest, vol.148, issue.1, pp.196-201, 2015.

P. W. Noble, C. Albera, W. Z. Bradford, U. Costabel, R. M. Du-bois et al., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials, Eur Respir J, vol.47, issue.1, pp.243-53, 2016.

V. Cottin, A. Schmidt, L. Catella, F. Porte, C. Fernandez-montoya et al., Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study, PLoS One, vol.12, issue.1, p.166462, 2017.

V. Cottin, B. Crestani, J. Cadranel, J. F. Cordier, S. Marchand-adam et al., French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis -2017 update. Full-length version, Rev Mal Respir, vol.34, issue.8, pp.900-68, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01647076

L. H. Lancaster, J. A. De-andrade, J. D. Zibrak, M. L. Padilla, C. Albera et al.,

, Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis, Eur Respir Rev, vol.26, issue.146, p.170057, 2017.

A. Tzouvelekis, T. Karampitsakos, P. Ntolios, V. Tzilas, E. Bouros et al., Longitudinal "real-world" outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece, vol.4, p.213, 2017.

J. A. Galli, A. Pandya, M. Vega-olivo, C. Dass, H. Zhao et al., Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions, Respirology, vol.22, issue.6, pp.1171-1179, 2017.

S. Harari, A. Caminati, C. Albera, C. Vancheri, V. Poletti et al., Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study, Respir Med, 2015.

U. Oltmanns, N. Kahn, K. Palmowski, A. Träger, H. Wenz et al., Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases, Respiration, vol.88, issue.3, pp.199-207, 2014.